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Abstract
Tumoral calcinosis is an uncommon disease characterized by tumor-like 
lesions composed of calcium salt. This condition is not a true neoplasm 
but an imbalance of calcium and phosphorus metabolism resulting from 
hereditary causes or secondary defects. Medical therapy to balance cal-
cium and phosphorus is the cornerstone of treatment. However, when pain 
or other compression symptoms occur, surgical excision is indicated. We 
report a 53-year-old man who presented with a swollen mass over his left 
shoulder with severe pain and a decreased range of motion for about 
6 months. He had a history of chronic renal failure and was on hemodialysis 
for 20 years. After serial examinations, hyperphosphatemia, hypocalcemia, 
and secondary hyperparathyroidism were diagnosed. Excision of the mass 
was performed. The pathological examination results revealed tumoral 
calcinosis. He was then referred to a nephrologist to adjust the medica-
tion, and dialysate was supplied to balance the calcium and phosphorus 
metabolism. He recovered well without significant complications or recur-
rence after 5 years of follow-up. [Tzu Chi Med J 2009;21(3):239–243]
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1. Introduction
Tumoral calcinosis is an uncommon clinical and his-
topathologic syndrome characterized by calcium salt 
deposits in periarticular regions [1]. Soft tissues of the 
shoulder, elbow, and hip regions are the most com-
monly involved areas. However, spinal and temporo-
mandibular joint involvement has also been reported. 
The extensor aspect of the joint is the usual site of 
the lesion, where it often connects with a synovial 
bursa [2].
We present a 53-year-old male patient who was 
diagnosed with tumoral calcinosis around his left 
shoulder and had surgical excision due to compres-
sion symptoms. He had a history of chronic renal 
failure with 20 years of hemodialysis therapy. After 
5 years of follow-up, he recovered well and no recur-
rence or lesions were found.
2. Case report
A 53-year-old man presented with a swelling mass over 
his left shoulder, and 6 months of reported severe 
pain and decreased range of motion. He had a history 
of chronic renal failure and had received hemodialysis 
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for 20 years during his initial presentation. In addi-
tion, he had taken approximately 1000 mg of calcium 
supplement per day for more than 10 years. He began 
to note the swelling mass in his left shoulder about 
6 months prior to this admission—the mass had en-
larged progressively. Due to failure of conservative 
treatment, he was referred to our clinic for further 
evaluation from a nephrologist.
Physical examination revealed a mass, about 6 cm 
in length, with a stiff and elastic consistency, located 
in the left shoulder area. The patient reported a pain-
ful sensation while palpating the mass. It limited ele-
vation and abduction of his left arm. The overlying 
skin was intact.
Plain radiographs showed a large periarticular mass 
with heterogeneously calcified density and bony de-
struction around the left distal end of the clavicle 
(Fig. 1). Magnetic resonance imaging (MRI) showed 
the heterogeneous consistency of the lesion, consist-
ing of multiple cavities alternating with calcified areas 
and compressing the surrounding structures (Fig. 2). 
Tumoral calcinosis was impressed and ultrasound 
examination of the neck was arranged, but no obvi-
ous abnormalities were noted.
The pertinent blood studies were within reference 
ranges except for blood urea nitrogen of 41 mg/dL 
(reference range, 9–23 mg/dL), creatinine of 8.4 mg/dL 
(reference range, 0.9–1.5 mg/dL), calcium of 7.4 mg/dL 
(reference range, 8.7–10.0 mg/dL), and phosphorus 
of 7.7 mg/dL (reference range, 2.2–4.3 mg/dL). Para-
thyroid hormone level was 228 pg/mL (reference range, 
12.1–60.6 pg/mL). Secondary hyperparathyroidism was 
impressed on admission.
An incision biopsy confirmed the diagnosis of tu-
moral calcinosis. The lesion was then excised (Fig. 3). 
The distal end of the clavicle was removed due to the 
advanced destruction. The soft mass was encircled 
by a thin layer of woven fibrous tissue that seemed to 
arise from the acromioclavicular joint capsule (Fig. 4). 
Histologically, the excised tissue contained fibrous 
septum with giant cells and granulation tissues sepa-
rating multiple lobules of calcium (Fig. 5).
After the operation, a nephrologist adjusted the 
medical and hemodialytic regimens for the patient. 
The dialysate was changed to a low calcium form 
and the intake of calcium supplements, high-calcium 
foods, and vitamin D were restricted. In addition, 
aluminum-hydroxide antacid was used to derivate the 
phosphate. After 3 months of management, the pa-
tient’s blood calcium, phosphate, and parathyroid 
hormone levels returned to within reference ranges.
Fig. 1 — Plain radiography of the left shoulder shows a 
large periarticular mass with heterogeneously calcified 
density and bony erosion around the left distal end of the 
clavicle.
A B
Fig. 2 — Magnetic resonance imaging shows a tumor with heterogeneous consistency and multiple cavities alternating 
with a calcified area: (A) coronal T1-weighted; (B) coronal T2-weighted.
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During the 5-year follow-up period, the patient’s 
blood calcium, phosphate, and parathyroid hormone 
levels were within reference ranges. The patient re-
ported marked clinical improvements. Physical exam-
ination revealed a normal range of motion, with no 
recurrence of the mass or any new lesion.
3. Discussion
Tumoral calcinosis is a tumor-like mass composed of 
calcium salt identified as calcium phosphates, cal-
cium carbonates, pyrophosphates, hydroxyapatites, 
or a combination of these substances resulting from 
metabolic imbalances of calcium and phosphate. 
The most common locations of tumoral calcinosis 
are the hip, elbow, shoulder, foot, and wrists (in 
descending order). They are often periarticular and 
large [1,3].
Tumoral calcinosis can be divided into primary or 
idiopathic and secondary categories [3]. Primary or 
idiopathic tumoral calcinosis, the most common 
form, has a familial correlation in 30% of cases, and 
an autosomal recessive pattern of inheritance is sug-
gested [4]. However, recent discoveries in the field of 
genetics have suggested that autosomal recessive 
mutations also play important roles in the metabolic 
dysregulation of phosphate [5,6]. Tumoral calcinosis 
often affects the black population in Africa during the 
first or second decade of life [7]. The pathogenesis 
includes enhancement in renal tubular phosphate 
reabsorption, reduced urinary calcium excretion, and 
increased 1,25-dihydroxy-vitamin D formation [4]. 
Prince et al [8] proposed an abnormality in the me-
tabolism of calcitriol and hyperphosphatemia (for the 
failure of its feedback).
The secondary form is associated with a wide 
variety of metabolic abnormalities of calcium and 
phosphorus, such as primary or secondary hyper-
parathyroidism, scleroderma, prolonged therapies of 
calcitriol or calcium carbonate, and clinical features 
that often compose the complex outline of patients 
with chronic renal failure on long-term hemodialysis.
In the secondary form of tumoral calcinosis, the 
main pathogenetic mechanism reaches critical lev-
els of serum calcium-phosphorus products of solu-
bility (Ca2+ × P > 70 mg/dL), creating the conditions for 
the precipitation of calcium salt in the soft tissues. 
In about half of patients with uremic tumoral calci-
nosis [9], the most frequent cause of this increase is 
secondary hyperparathyroidism. In patients without 
hyperparathyroidism, an increase in serum of Ca2+ × P 
Fig. 3 — The mass and distal end of the clavicle were 
excised.
Fig. 4 — Photograph showing the mass lesion, measuring 
about 5 cm in diameter, with a thin woven layer of fibrous 
pseudocapsule with multiple lobules of calcium deposits.
Fig. 5 — Photomicrograph showing amorphous calcified 
foci surrounded by fibrous cicatrix tissue (hematoxylin & 
eosin; original magnification, 200´).
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can be caused by iatrogenic hypercalcemia or severe 
hyperphosphatemia of multifactorial etiologies, such 
as prolonged or excessive administration of calcium 
carbonate and calcitriol, inadequate phosphorus 
chelating therapy, and insufficient dialysis. The dura-
tion of dialysis has been cited as a predisposing fac-
tor to the development of uremic tumoral calcinosis, 
and the risk of occurrence increases with the number 
of years of hemodialysis, despite normal values of 
Ca2+ × P [10].
Tumoral calcinosis often consists of masses of 
multilobulated tissues of varying diameters, with fi-
brovascular septa that enclose areas of whitish calci-
fications with chalky firmness. They occur as multiple 
masses in two thirds of patients and are often firmly 
attached to muscles, underlying fascia, tendons, or 
the capsular joint. They may also infiltrate these 
structures [11]. Growth of these lesions is usually 
slow and progressive, often taking place during many 
years. Sometimes, ulceration of the overlying skin 
occurs, causing secondary infections.
The masses are usually asymptomatic unless they 
enlarge enough to compress the surrounding tissues. 
The main symptoms are discomfort, swelling, pain, 
and joint limitation. Neurovascular compression is 
sometimes reported as compression of the ulnar 
nerve, median nerve in the carpal tunnel, and the 
sciatic nerve. The main joints involved are the shoul-
der, elbow, and hip. However, rare locations such as 
the spine, temporomandibular joint, hand and fingers, 
and knee extensor have also been described.
Radiographically, tumoral calcinosis is a calcified, 
lobulated, homogeneous mass, with rounded opacity 
separated by thin radiolucent lines that give it a so-
called chicken wire appearance. MRI shows multiple 
cavities of low-signal density on T1- and T2-weighted 
sequences. Scintigraphy is useful, especially for the 
identification of multiple lesions and for assessing 
the results of the therapy.
Many periarticular masses may mimic the present-
ing pictures of tumoral calcinosis. The possible dif-
ferential diagnoses are outlined in Table 1. History, 
physical examinations, radiographic pictures, and lab-
oratory examination results must be accessed care-
fully before beginning the definite management [3].
Many reports have outlined various treatments of 
metabolic disorders and symptoms. Increased calcium-
phosphorus serum products should be regulated. 
Regulation of hyperphosphatemia must be the first 
target. It is lowered by dietary deprivation of phos-
phorus, combined with phosphate-binding chelating 
agents, which have provided satisfactory results, clin-
ical improvement, and often a reduction in the mass 
[12,13]. The induction of a negative calcium balance 
may also be obtained by an increased number of di-
alysis sessions, with low Ca2+ dialysate concentration 
[14]. Patients who underwent renal transplantation 
showed marked improvement in the complete re-
gression of tumoral calcinosis [10]. Alternative medi-
cal treatments include the administration of steroids, 
diphosphonates, or calcitonin—but research has 
shown these to be unsuccessful [15].
Patients with secondary hyperparathyroidism have 
shown improvements in their clinical symptoms, and 
the progression of soft-tissue calcification has been 
halted after subtotal parathyroidectomy [16]. However, 
the operation should be reserved for the most severe 
patients with multifocal tumoral calcinosis.
In summary, tumoral calcinosis is an imbalance of 
calcium and phosphorus metabolism. It is often found 
in patients with chronic renal failure and prolonged 
hemodialysis in Taiwan. Corrections of electrolyte 
imbalances and hormone abnormalities are the cor-
nerstone of treatment. Once severe pain or other 
compression symptoms develop, surgical excision is 
indicated. After the operation, adjustment of medi-
cations, food, and dialysate to balance calcium and 
phosphorus metabolism is necessary to prevent the 
recurrence of old lesions as well as occurrence of new 
lesions.
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